Skip to main content
Premium Trial:

Request an Annual Quote

NextGen Developing Biomarker Assays for Takeda

Premium

This story originally ran on Feb. 3.

Biomarker firm NextGen Sciences this week announced it has entered into an agreement with Takeda Pharmaceutical to develop validated protein biomarker assays.

Terms of the agreement were not disclosed.

The assays will be used by Takeda in preclinical and clinical studies "to support their drive toward personalized medicine," NextGen said in a statement. The company added that the assays will be designed to target specific protein isoforms found in liver and muscle in multiple species. NextGen's multiple-reaction monitoring platform will be used.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.